{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-004786","form_type":"8-K","ticker":null,"cik":"0001792581","company_name":"Kiromic Biopharma, Inc.","filed_at":"2024-04-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.137146+00:00","generated_at":"2026-06-04T01:54:05.864457+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kiromic BioPharma issues $2M senior secured convertible note at 25%, convertible at $2.50","bullets":["Issued $2,000,000 25% Senior Secured Convertible Promissory Note to an accredited investor.","Note matures April 2, 2025; interest rate 25% (27% upon default).","Initial conversion price $2.50 per share, with 19.99% beneficial ownership limitation.","Note secured by all fixtures, equipment, and intellectual property of the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-004786","json":"https://secwatch.observer/filing/0001558370-24-004786.json","markdown":"https://secwatch.observer/filing/0001558370-24-004786.md","text":"https://secwatch.observer/filing/0001558370-24-004786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024004786/0001558370-24-004786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024004786/krbp-20240402x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T01:54:05.864457+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6fffc75cc7bc6afc91952d83987b36d380d2cc9","claim":"Kiromic Biopharma, Inc. entered into 25% Senior Secured Convertible Promissory Note with an accredited investor valued at principal amount $2,000,000; 25% interest per annum; convertible at $2.50 per share (effective 2024-04-02).","evidence_excerpt":"On April 2, 2024, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837024004786/0001558370-24-004786-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Value","value":"principal amount $2,000,000; 25% interest per annum; convertible at $2.50 per share"},{"label":"Effective","value":"2024-04-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}